Belatacept denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belatacept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Belatacept

Belatacept is classified as a specialty biologic, and UnitedHealthcare requires prior authorization (PA) before dispensing it. A PA-required denial — sometimes issued as a claim denial when the drug is administered or dispensed without an approved PA on file — does not mean UHC will ultimately refuse to cover belatacept. It means the correct coverage pathway was not followed, or that a submitted PA request did not satisfy every documentation element in UHC's specialty pharmacy criteria.

## Why This Denial Is Appealable

If your prescriber submitted a PA and it was denied for clinical reasons (e.g., insufficient documentation of need), you have the right to appeal that clinical determination. If the claim was denied solely because a PA was not obtained in advance due to urgent transplant circumstances, you may have grounds for a retroactive authorization request. Either path is viable with the right documentation.

## Federal Appeal Framework

• ACA §2719 external review: After exhausting UHC's internal appeal process, an independent IRO can review whether the PA denial was consistent with accepted transplant-medicine standards. Deadlines are approximately four months from denial — confirm the exact date on your EOB.
• ERISA §503: Employer-plan members can demand the specific PA criteria and the clinical evidence UHC relied on.
• Expedited review: If the patient is a transplant recipient at risk from delayed immunosuppression, expedited internal and external review can compress timelines significantly.

## Concrete Appeal Steps

1. Obtain the PA denial letter and the full list of UHC's prior-authorization criteria for belatacept. 2. Identify which criterion was deemed unmet. 3. Work with the transplant team to gather the missing documentation and resubmit, or if resubmission has failed, file a formal internal appeal. 4. Request expedited review if clinically urgent. 5. If the internal appeal is unsuccessful, file for external IRO review immediately.

## Documentation to Gather

• Transplant confirmation: operative note, pathology, organ type, transplant date.
• Current immunosuppressive regimen history: all agents used post-transplant with dates and outcomes, establishing the clinical progression that led to belatacept.
• Rejection or toxicity episodes: chart notes with dates documenting any acute rejection, calcineurin-inhibitor toxicity, or other complication relevant to the choice of belatacept.
• Prescriber PA support letter: addresses each UHC criterion individually, references the FDA-approved prescribing label, and invokes the applicable transplant guideline organization without citing specific numbers.

## Criteria-Mapping Structure

Download the current UnitedHealthcare prior-authorization criteria for belatacept from UHC's provider portal or request it in writing. For each criterion, create a two-column table pairing the exact policy language with the chart fact (document name, date, and finding) that satisfies it. Submit this table with the appeal so no criterion is left unaddressed.